We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Vitamin D Increases Survival of Breast Cancer Patients

By LabMedica International staff writers
Posted on 23 Mar 2014
Breast cancer patients with high levels of vitamin D in their blood have been found to be twice as likely to survive the disease as women with low levels of this nutrient, according to new research.

According to the US National Institutes of Health (NIH; Bethesda, MD, USA), the current recommended daily allowance for vitamin D is 600 IU for adults and 800 IU for people over 70 years old. More...


University of California, San Diego School of Medicine (La Jolla, USA) researchers reported their findings in the March 2014 issue of the journal Anticancer Research. In earlier research, Cedric F. Garland, DrPH, professor in the department of family and preventive medicine, showed that low vitamin D levels were linked to a high risk of premenopausal breast cancer. That finding, he said, prompted him to question the relationship between 25-hydroxyvitamin D—a metabolite produced by the body from the ingestion of vitamin D—and breast cancer survival rates.

Dr. Garland and colleagues performed a statistical analysis of five studies of 25-hydroxyvitamin D obtained at the time of patient diagnosis and their follow-up for a median of nine years. Combined, the studies included 4,443 breast cancer patients. “Vitamin D metabolites increase communication between cells by switching on a protein that blocks aggressive cell division,” said Dr. Garland. “As long as vitamin D receptors are present tumor growth is prevented and kept from expanding its blood supply. Vitamin D receptors are not lost until a tumor is very advanced. This is the reason for better survival in patients whose vitamin D blood levels are high.”

Women in the high serum group had an average level of 30 ng/mL of 25-hydroxyvitamin D in their blood. The low group averaged 17 ng/mL. The average level in patients with breast cancer in the United States is 17 ng/mL. “The study has implications for including vitamin D as an adjuvant to conventional breast cancer therapy,” said coauthor Heather Hofflich, DO, UC San Diego associate professor in the department of medicine.

Garland recommended randomized controlled clinical trials to confirm the findings but suggested physicians consider adding vitamin D into a breast cancer patient’s standard care now and then closely monitor the patient. “There is no compelling reason to wait for further studies to incorporate vitamin D supplements into standard care regimens since a safe dose of vitamin D needed to achieve high serum levels above 30 ng/mL has already been established,” said Dr. Garland.

A 2011 meta-analysis by Dr. Garland and colleagues estimated that a serum level of 50 ng/mL is tied to a 50% lower risk of breast cancer. Whereas there are some variations in absorption, those who consume 4,000 International Units (IU) per day of vitamin D from food or a supplement typically would reach a serum level of 50 ng/ml. Dr. Garland advised patients to ask their healthcare provider to measure their levels before substantially increasing vitamin D intake.

Related Links:

University of California, San Diego School of Medicine



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.